BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38254333)

  • 1. Anticancer Effect of Theranekron
    Erzurumlu Y; Doğan HK; Çataklı D
    Turk J Pharm Sci; 2024 Jan; 20(6):368-373. PubMed ID: 38254333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate fibroblasts enhance androgen receptor splice variant 7 expression in prostate cancer cells.
    Sasaki T; Yoshikawa Y; Kageyama T; Sugino Y; Kato M; Masui S; Nishikawa K; Inoue T
    Prostate; 2023 Mar; 83(4):364-375. PubMed ID: 36479717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the effects of androgenic Chinese herbal medicines on androgen receptors and tumor growth in experimental prostate cancer models.
    Zhang ZB; Ip SP; Cho WC; Hu Z; Huang YF; Luo DD; Xian YF; Lin ZX
    J Ethnopharmacol; 2020 Oct; 260():113058. PubMed ID: 32525068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
    Karelia DN; Kim S; Plano D; Sharma AK; Jiang C; Lu J
    Prostate; 2023 Jan; 83(1):16-29. PubMed ID: 35996318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
    Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
    Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells.
    Ghashghaei M; Niazi TM; Heravi M; Bekerat H; Trifiro M; Paliouras M; Muanza T
    Prostate; 2018 Jan; 78(1):64-75. PubMed ID: 29134684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of sLZIP in cyclin D3-mediated negative regulation of androgen receptor transactivation and its involvement in prostate cancer.
    Kim Y; Kim J; Jang SW; Ko J
    Oncogene; 2015 Jan; 34(2):226-36. PubMed ID: 24441043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White button mushroom (Agaricus bisporus) disrupts androgen receptor signaling in human prostate cancer cells and patient-derived xenograft.
    Wang X; Ha D; Mori H; Chen S
    J Nutr Biochem; 2021 Mar; 89():108580. PubMed ID: 33388344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.
    Kokontis JM; Lin HP; Jiang SS; Lin CY; Fukuchi J; Hiipakka RA; Chung CJ; Chan TM; Liao S; Chang CH; Chuu CP
    PLoS One; 2014; 9(10):e109170. PubMed ID: 25271736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors.
    Mir H; Kapur N; Singh R; Sonpavde G; Lillard JW; Singh S
    Cell Cycle; 2016; 15(6):819-26. PubMed ID: 27029529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
    Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
    Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New mode of action of curcumin on prostate cancer cells: Modulation of endoplasmic reticulum-associated degradation mechanism and estrogenic signaling.
    Erzurumlu Y; Dogan HK; Catakli D
    J Biochem Mol Toxicol; 2024 Jan; 38(1):e23636. PubMed ID: 38229314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
    He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
    Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of a novel androgen receptor target gene, the cyclin B1 gene, through androgen-dependent E2F family member switching.
    Li Y; Zhang DY; Ren Q; Ye F; Zhao X; Daniels G; Wu X; Dynlacht B; Lee P
    Mol Cell Biol; 2012 Jul; 32(13):2454-66. PubMed ID: 22508987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Nakayama H; Sekine Y; Oka D; Miyazawa Y; Arai S; Koike H; Matsui H; Shibata Y; Suzuki K
    Prostate; 2022 Feb; 82(3):314-322. PubMed ID: 34843630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.
    Khurana N; Kim H; Chandra PK; Talwar S; Sharma P; Abdel-Mageed AB; Sikka SC; Mondal D
    Oncol Rep; 2017 Nov; 38(5):2774-2786. PubMed ID: 28901514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
    Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A
    Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.